Novel Targets and Treatments in Oncology and Immunology

Takeda Pharmaceutical are launching an open innovation initiative, inviting researchers to submit their ideas and technologies across five different focus areas, up to £85k / €100k / $150k (AUD). Summarised below are the interests of Takeda relating to novel targets and treatments in oncology and immunology. In the attached application form, each of these subtopics have been expanded upon to give further detail of proposals that would be within scope. In the attached application form, each of these topics have been expanded upon to give further detail of proposals. 

Submissions should be relevant to one or more of the following titles: 

• REF#13: Research on induction of anti‑tumour effects of cells in the tumour microenvironment, particularly Treg, macrophage, fibroblast, and neutrophil, in cold tumours insensitive to immune checkpoint inhibitors
• REF#14: Development of CAR-engineered immune cells including T/NK cell products against novel solid and/or haematological malignancies targets
• REF#15: Research and development toward realization of innovative technology for next generation cellular cancer immuno-therapy

Jurisdictions of Interest

Only submissions from Europe and Australia will be eligible for this campaign.

Submission Information

To view more details on each area of interest seeking proposals for funding, download an application form here. For an FAQ covering subjects like funding and IP terms, click here. To submit your proposal, please visit discover.in-part.com, register, and submit as a Research Project under the appropriate Discover campaign.